aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

aTyr Pharma, Inc.NASDAQ: ATYR

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $645K fell 27.7% year over year, behind the -10.4% change in trailing-twelve-month other income / expenses. Sequentially, it fell 22.5% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.

Context

  • Other income / expenses amounted to 1846.8% of revenue in FY2025, up 190.7 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -27.7% toward the trailing-twelve-month pace of -10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$645K-22.5% QoQ
Last fiscal yearDec 2025
$3.51M-9.8% YoY
LTMMar 2026
$3.26M-10.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.7%——
1 year-9.8%——
3-year CAGR+49.0%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
3.51M USD
Year-over-year change
-9.8%
4-year CAGR
+96.0%

Other Income / Expenses vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.4% is the 2nd highest of 8, against a peer median of -64.6%.
  • Other income / expenses amounts to 1714.2% of revenue for ATYR, versus a peer median of 11.9%.
ATYR Competitors
Other Income / Expenses for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M USD-46.1%+60.9%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$3.26M USD-10.4%+49.0%1714.2%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$2.3M USD-64.6%-16.7%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$1.47M USD-57.0%-25.8%—
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$1.17M CAD+96.8%—6.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$5.37M USD-124.3%—11.9%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$9.98M USD-163.6%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$34.27M USD-2325.3%—871.1%
Peer median (excluding ATYR) —-64.6%-16.7%11.9%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue010.39M353K235K190K
Cost of Revenue1.3M1.7M001.55M
Gross Profit(1.3M)8.69M353K235K(1.36M)
Gross Margin—83.7%100.0%100.0%-717.4%
Research & Development23.26M42.81M42.29M54.37M60.22M
Selling, General & Admin10.75M12.29M12.98M13.78M17.6M
Operating Expenses32.71M55.1M55.27M68.15M76.26M
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
EBITDA(32.47M)(43.65M)(47.66M)(62.48M)(72.57M)
EBITDA Margin—-420.3%-13500.3%-26588.1%-38192.1%
Operating Income(34.02M)(46.4M)(54.92M)(67.91M)(77.63M)
Operating Margin—-446.8%-15557.8%-28899.6%-40856.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses238K1.06M4.52M3.89M3.51M
Income Before Tax(33.78M)(45.34M)(50.4M)(64.02M)(74.12M)
Pre-Tax Margin—-436.6%-14276.8%-27243.4%-39009.5%
Income Tax Expense00000
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Net Margin—-436.5%-14274.5%-27243.8%-39009.5%
EPS (Basic)(1.77)(1.60)(0.94)(0.86)(0.80)
EPS (Diluted)(1.77)(1.60)(0.94)(0.86)(0.80)
Weighted Avg Shares19.08M28.42M53.61M74.26M92.99M
Weighted Avg Shares (Diluted)19.08M28.42M53.61M74.26M92.99M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.